Skip to main content
SpringerLink
Log in

Global data confirm positive safety profile of rivaroxaban

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The three studies were: XANTUS (enrolled patients from Western and Eastern Europe, Canada and Israel); XANAP (enrolled patients from the Asia-Pacific region); and XANTUS-EL (enrolled patients from Eastern Europe, Middle East, Africa and Latin America).

References

  1. Kirchhof P, et al. Global Prospective Safety Analysis of Rivaroxaban. Journal of the American College of Cardiology 72: 141-53, No. 2, 10 Jul 2018. Available from: URL: https://doi.org/10.1016/j.jacc.2018.04.058.

    Article  CAS  PubMed  Google Scholar 

  2. Healey JS. Stroke Prevention in Atrial Fibrillation: What Is Real World, and What Do Real-World Data Reveal? Journal of the American College of Cardiology 72: 154-5, No. 2, 10 Jul 2018. Available from: URL: https://doi.org/10.1016/j.jacc.2018.04.057.

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Global data confirm positive safety profile of rivaroxaban. Reactions Weekly 1709, 9 (2018). https://doi.org/10.1007/s40278-018-48420-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-48420-8

Search

Navigation